-
2023-509216-28-00
4
2019-05-27
Generalized Pustular Psoriasis
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2023-506733-30-00
4
2019-05-16
Multiple Myeloma relapsed and/or refractory
-
2024-513396-41-00
5
2019-05-15
PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE >= 65 YEARS OR N
-
2024-512667-31-00
5
2019-04-23
Main cohort: Patients with unresected Stage I/II, lymph-node negative
-
2024-510985-17-00
4
2019-03-14
First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive
-
2023-503812-34-00
4
2019-02-13
Locally Advanced or Metastatic Disease in Solid Tumors
-
2024-511204-16-00
5
2019-01-23
Metastatic breast cancer
-
2022-502937-24-00
5
2019-01-02
Atopic Dermatitis
-
2022-501485-22-00
5
2018-12-18
Myelodysplastic syndrome (MDS)
-
2023-510517-26-00
9
2018-10-26
Acute Myeloid Leukemia
-
2023-506994-36-00
5
2018-10-11
Ulcerative Colitis
-
2023-507657-15-00
5
2018-09-13
Ulcerative Colitis
-
2023-504820-24-00
5
2018-03-21
Neoadjuvant/Adjuvant treatment for participants with Resectable Stage
-
2024-512212-21-00
5
2017-11-28
Advanced hepatocellular carcinoma (HCC)
-
2023-504951-29-00
5
2017-07-27
Chron's Disease
-
2023-509671-17-00
5
2017-07-12
Breast Cancer
-
2023-509169-19-00
5
2017-07-11
Advanced ALK positive non-small cell lung cancer
-
2024-514686-19-00
4
2017-03-10
Relapsed or Refractory Chronic Lymphocytic Leukemia
-
2023-505699-31-00
5
2017-01-02
Ulcerative Colitis
-
2023-507889-89-00
5
2016-02-19
Respiratory tract infection
-
2022-501253-37-00
4
2016-02-02
(A) Anal Squamous Cell Carcinoma,
(B) Biliary Adenocarcinoma (gallblad
-
2023-505246-26-00
5
2016-01-27
High- or very-high risk, localized or locally advanced prostate cancer
-
2024-511348-25-00
10
2015-12-11
Myelodysplastic syndromes (MDS)